Voluntary nationwide recall: Sucralfate (Nostrum – July)

Jul. 2025Pharmacy Updates

Nostrum Laboratories, Inc. is recalling all lots of Sucralfate Tablets USP 1 gram. Sucralfate is used for the prevention and treatment of certain stomach ulcers.

Nostrum Labs filed bankruptcy on Sept. 30, 2024. In connection with that filing, the company has ceased and shut down operations. Nostrum Labs is initiating a voluntary recall of Sucralfate Tablets USP 1 gram, all lots within expiry, as a result of the closures and discontinuation of its quality activities. This recall pertains only to Sucralfate Tablets USP 1 gram manufactured by Nostrum Labs after June 2023. No other Nostrum Labs products are affected by this recall. Using a product that may not meet quality standards means that the company is unable to confirm that the product has the correct identity, strength, quality, and purity characteristics.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Sucralfate, you should talk to your doctor before stopping the medication.

As of July 11, 2025, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.


Recent Announcements

Virtual Institute: Bridging the Gap: Foundations of Integrated Care CME Courses Available

Bridging the Gap: Foundations of Integrated Healthcare is a free educational series designed to support behavioral health and physical health providers in integrating physical health and wellness strategies into their practices and programs to support recovery of individuals living with serious mental illnesses. The series emphasizes tools, education, and resources that empower healthcare providers and individuals to become informed and effective managers of their health and health care.
Jun. 2026Education/Webinars

Important information regarding Medicare GLP-1 Bridge through CMS

The Centers for Medicare & Medicaid Services (CMS) is expanding access to certain GLP-1 medications through the Medicare GLP-1 Bridge short-term demonstration starting July 1, 2026.
Jun. 2026Important Notices

CME/CEU Webinar: Bright Beginnings: The Role of Medical and Dental Providers in Early Oral Health

Please join us for a live, CME-accredited and CEU-accredited webinar on Monday, Aug. 24 from noon to 1 p.m., that will educate providers on the importance of early childhood oral health.
Jun. 2026Education/Webinars